News

Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 Supporting Differentiated Profile In Sickle Cell Disease (SCD) At European Hematology ...
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of ...
Rolling Out7d
Why some people escape sickle cell pain forever
You might have wondered why some people with sickle cell disease seem to live relatively normal lives while others spend half their time in the hospital writhing in agony from pain crises. It’s the ...
The Manila Times12d
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
"Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe ...
Finanznachrichten1mon
Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and ...
Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to ...
Morningstar1mon
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...
Seeking Alpha4mon
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
This edit results in the production of high levels of fetal hemoglobin (HbF ... from the cell surface to improve the persistence of the CAR T cells in an “off-the-shelf” setting.
manilatimes4mon
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...
The Globe and Mail4mon
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...
sicklecellanemianews5mon
SCD patients free of VOEs after treatment with gene-editing therapy
The treatment also increased total hemoglobin levels and was well tolerated ... to introduce genetic changes that mimic those naturally found in people with hereditary persistence of fetal hemoglobin, ...
GEN7mon
Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning
All four patients experienced rapid and robust fetal hemoglobin (HbF) induction by Month 1 (>60%) and corresponding sickle hemoglobin (HbS) reduction (≤36%) in non-transfused blood, which was ...
Nasdaq1y
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal ...